ASXLetter to Shareholders, Notice of AGM & Proxy Form
other announcement
OCC
Orthocell
Pharmaceuticals, Biotechnology & Life Sciences
Orthocell is a leader in the regenerative medicine sector, focusing on innovative treatments for chronic degenerative diseases and injuries. The company specializes in developing collagen medical devices and cell therapies that leverage the body's natural repair mechanisms. Orthocell's products are designed to enhance surgical repair and promote tissue regeneration, positioning it as a pioneer in the biotechnology and life sciences industry.
Short position
short percentage0.03%
reported shorts69.3K
shares on issue272.394M
Orthocell (ASX:OCC) has 0.03% of its shares on issue reported as short positions as of 5 Oct 2026, or about 69,327 shares. Over the past 30 days that figure has fallen 0.24 percentage points, and over 90 days it has fallen 0.34 percentage points. Its highest recorded short interest was 0.94% in December 2025. OCC is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Orthocell (OCC) News
Latest articles and price-sensitive announcements with AI sentiment classification.
StockheadOrthocell lands first Remplir sales in Thailand
The first sales follow Thai FDA approval and Orthocell’s appointment of MediTime as exclusive in-country distributor for Remplir. ... Read More The post Orthocell lands first Remplir sales in Thailand appeared first on Stockhead.
Orthocell Achieves First Remplir Sales in Thailand
other announcement
Google NewsOrthocell (ASX:OCC) on the Radar: What Could Drive the Next Move in September 2026? - Kalkine
Orthocell (ASX:OCC) on the Radar: What Could Drive the Next Move in September 2026? Kalkine
Application for quotation of securities - OCC
other announcement
Date of AGM & Closing Date for Director Nominations
other announcement
Could Orthocell (ASX: OCC) Be One of the ASX’s Most Interesting Healthcare Stories? - Kalkine
Could Orthocell (ASX: OCC) Be One of the ASX’s Most Interesting Healthcare Stories? Kalkine
KalkineWhat’s Next for Orthocell (ASX:OCC) After Growth Update?
Highlights Orthocell has presented its regenerative medicine platform to an international audience at a major growth conference overseas. The Perth-based company's collagen and cell therapy products continue to expand their footprint across multiple global markets. Steady cash reserves and an absence of debt underpin the company's ability to fund its ongoing global expansion plans. Orthocell Ltd, the Perth-based regenerative medicine company behind a range of collagen and cell therapy product...
Why Does Orthocell (ASX:OCC) Matter Now Among ASX Healthcare Stocks?
Highlights Orthocell is in focus after a fresh company disclosure added new context to the public record. The healthcare stocks lens centres on clinical progress, regulatory pathways, commercial execution and funding discipline. The broader Australian market backdrop remains important when reading company-specific developments. Australian shares are being assessed against a shifting mix of company updates, sector conditions and global market signals, making fresh disclosures especially import...
Orthocell Canaccord Genuity Conference Live Webcast
other announcement
Orthocell (ASX:OCC) Delivers Record Revenue While US Remplir Growth Remains Key Focus - Kalkine
Orthocell (ASX:OCC) Delivers Record Revenue While US Remplir Growth Remains Key Focus Kalkine
Orthocell to Present at Canaccord Growth Conference
other announcement
Orthocell (ASX:OCC) Shares Slip as Investors Assess Regenerative Medicine Opportunity - Kalkine
Orthocell (ASX:OCC) Shares Slip as Investors Assess Regenerative Medicine Opportunity Kalkine
Change of Registered Office & Principal Place of Business
other announcement
Why Is Regenerative medicine group Orthocell (ASX:OCC) Turning Heads Right Now?
Highlights Commercial momentum in regenerative medicine and a fresh patent win kept ASX small-cap healthcare in focus this week. Orthocell and Recce Pharmaceuticals show how milestones can reshape the story for emerging medical names. Market participants are watching revenue traction, regulatory progress and intellectual property across the two companies. Regenerative medicine group Orthocell (ASX:OCC), a West Australian developer of nerve-repair and tissue-regeneration products, stood out acro...
Orthocell Limited Issues 62,894 Shares to Directors Under Employee Awards Plan, Boosting Total Share Capital
Orthocell Limited (ASX: OCC) has applied for quotation of 62,894 ordinary fully paid shares issued to its directors on 17 July 2026 as part of director fee compensation under the company's Employee Awards Plan. These shares were issued at AUD 0.75610000 each and had prior shareholder approval at the 2025 annual general meeting. Upon quotation, Orthocell's total issued ordinary fully paid share capital will increase to 272,316,531 shares on the ASX. Key Points Orthocell Limited (OCC) issued 62...
Orthocell Grants 263,895 Retention Rights and 99,264 Performance Rights to Employees Under Employee Awards Plan
On 17 July 2026, Orthocell Limited (ASX: OCC) issued a total of 363,159 unquoted employee incentive securities, consisting of 263,895 retention rights and 99,264 performance rights. These grants were made under the company’s Employee Awards Plan and did not require shareholder approval pursuant to ASX Listing Rule 7.2 exception 13. This latest equity allocation reflects Orthocell’s ongoing commitment to align employee incentives with long-term shareholder value creation within the biomedical...
Why Is Regenerative medicine group Orthocell (ASX:OCC) Turning Heads Right Now?
Highlights Commercial momentum in regenerative medicine and a fresh patent win kept ASX small-cap healthcare in focus this week. Orthocell and Recce Pharmaceuticals show how milestones can reshape the story for emerging medical names. Market participants are watching revenue traction, regulatory progress and intellectual property across the two companies. Regenerative medicine group Orthocell (ASX:OCC), a West Australian developer of nerve-repair and tissue-regeneration products, stood out acro...
Orthocell Shares Rise: What Could Drive the Regenerative-Medicine Stock's Next Move? - Kalkine
Orthocell Shares Rise: What Could Drive the Regenerative-Medicine Stock's Next Move? Kalkine
Orthocell (ASX:OCC) Expands Global Reach With Strong Revenue Momentum
Highlights Record annual revenue reflects expanding commercial footprint. Remplir adoption continues to grow across key international markets. Strong financial position supports global expansion strategy. Orthocell continues to strengthen its position in regenerative medicine through growing demand for its flagship products, expanding international market access, increasing hospital adoption, and advancing regulatory milestones across multiple regions. ...
Record revenue for Orthocell as Remplir rollout gathers pace in US
Orthocell records record June quarter revenue of $3.8 million and record FY26 revenue of $13.2 million, up 44% year-on-year ... Read More The post Record revenue for Orthocell as Remplir rollout gathers pace in US appeared first on Stockhead.
Why Is Orthocell (ASX:OCC) in Focus Over Its Cash Position?
Highlights Orthocell continues maintaining a debt-free balance sheet while advancing regenerative medicine programs. Growing revenue and available cash resources are supporting the company's commercial expansion strategy. Regulatory progress and product commercialisation remain key drivers for the healthcare company. Orthocell Ltd (ASX:OCC) has attracted renewed market attention as its financial position continues supporting the commercial expansion of its regenerativ...
StockTake: Orthocell expands Remplir into Thailand
MediTime will be the exclusive distributor of Remplir Thailand following regulatory approval to commercialise Remplir in the country. ... Read More The post StockTake: Orthocell expands Remplir into Thailand appeared first on Stockhead.
Orthocell (ASX:OCC) Advances Commercial Strategy with Thailand Distributor - Kalkine
Orthocell (ASX:OCC) Advances Commercial Strategy with Thailand Distributor Kalkine
Small CapsOrthocell Appoints Thailand Distributor for Remplir
other announcement
Orthocell sends second Remplir shipment to war-torn Ukraine
Is expanding the humanitarian reach of its flagship nerve repair product Remplir in Ukraine, with an additional shipment being sent ... Read More The post Orthocell sends second Remplir shipment to war-torn Ukraine appeared first on Stockhead.
Clinical Outcomes See Expanded Use of Remplir in the Ukraine
other announcement
Orthocell records first sales of flagship nerve repair product Remplir in Canada
Orthocell records first sales of Remplir in Canada ... Read More The post Orthocell records first sales of flagship nerve repair product Remplir in Canada appeared first on Stockhead.
First Sales of Remplir Achieved in US$75m Canadian Market
other announcement
Orthocell’s nerve repair product Remplir posts near-90pc success rate as global rollout gains momentum
Data to support continued US expansion and planned European market entry, with approval targeted for H2 CY26 ... Read More The post Orthocell’s nerve repair product Remplir posts near-90pc success rate as global rollout gains momentum appeared first on Stockhead.
Compelling 90% Success Rate for Remplir in Real World Study
other announcement
Motley FoolOrthocell caps 26% surge this week with first US Military Surgery
The company's commercial rollout is off to a good start. The post Orthocell caps 26% surge this week with first US Military Surgery appeared first on The Motley Fool Australia.
Is Orthocell (ASX:OCC) Expanding Its Role in ASX All Ordinaries Biotech Sector?
Highlights Orthocell completes first Remplir procedure in US military hospital network. Healthcare sector activity reflects medical technology adoption and expansion. Market participation highlights integration of biotech companies within ASX indices. Orthocell completes a Remplir procedure in a US military hospital network, highlighting clinical deployment and biotechnology sector participation within ASX All Ordinaries. The healthcare and biotechnology sector represents a significant ...
First Surgical Use of Remplir in US Department of Defense
other announcement
Break it Down: Orthocell approved to sell Remplir to US defence hospital network
Orthocell gets Remplir approval across the US Department of Defence and Veterans Affairs hospital networks. ... Read More The post Break it Down: Orthocell approved to sell Remplir to US defence hospital network appeared first on Stockhead.